Drug Update · Dermatology

Dupilumab (Dupixent) Label Updated for Pediatric CSU, Weight-Based Dosing from 2 Years

September 12, 2026

New Indication

Chronic spontaneous urticaria in patients aged 2 years and older who remain symptomatic despite H1 antihistamine treatment [2]

Pediatric dosing 2–5 years

5 to <15 kg: 200 mg Q4W; 15 to <30 kg: 300 mg Q4W [2]

LIBERTY-CSU CUPID A HRQoL results

DLQI difference -3.2 (95% CI -5.2 to -1.1); CU‑Q2oL difference -8.6 (95% CI -14.6 to -2.6) at Week 24 [8]

Label revision

DailyMed revised April 2026; FDA label metadata notes supplemental approval date 2026-07-15 [2][9]

Clinical Perspective

This update affects healthcare providers treating pediatric and adult patients with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamines by providing an FDA‑label indication and pediatric weight-based dosing for patients aged 2 years and older ^[1]. The source‑confirmed trial data support HRQoL improvements with dupilumab in omalizumab-naïve CSU patients and the label provides specific weight-based regimens for pediatric age groups 2–5 years and 6–17 years, as well as adult dosing for CSU ^[2]^[1]. How dupilumab will be positioned relative to other second-line biologic therapies for pediatric CSU (for example, comparative effectiveness versus omalizumab) remains an open clinical question?

Dr. Divya Agarwal, MBBS, MD (Dermatology, Venereology & Leprosy) · Dermatology

Dupilumab (Dupixent) labeling was updated in April 2026 to include chronic spontaneous urticaria (CSU) for adult and pediatric patients aged 2 years and older who remain symptomatic despite H1 antihistamine treatment, with weight-based pediatric dosing guidance added to the label ^[1]. The change is reflected in the revised prescribing information dated April 2026 and is supported by phase 3 trial data showing improvements in health-related quality of life measures in patients with CSU in the LIBERTY-CSU CUPID Study A ^[1]^[2].

Clinical Context

Dupilumab is a human monoclonal IgG4 directed against the interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling; the mechanism is described in the prescribing information as blockade of IL-4 and IL-13 cytokine-induced inflammatory responses via IL-4Rα binding ^[3]. Dupilumab (Dupixent) is marketed by Sanofi-Aventis U.S. LLC and is administered by subcutaneous injection; the prescribing information lists multiple indications including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, bullous pemphigoid, allergic fungal rhinosinusitis and now chronic spontaneous urticaria ^[1]^[3]. The updated CSU indication specifies use for patients aged 2 years and older who remain symptomatic despite H1 antihistamine treatment and notes limitations that it is not indicated for other forms of urticaria ^[1].

Key Findings

The LIBERTY-CSU CUPID Study A, a double-blind phase 3 trial in patients aged ≥6 years with CSU who remained symptomatic despite H1-antihistamine treatment, randomized patients to dupilumab 300 mg every 2 weeks (q2w; n = 70) or placebo q2w (n = 68) and evaluated changes in health-related quality of life (HRQoL) at Week 12 and Week 24 ^[2].
Clinicians should consult current prescribing information for full dosing guidance.
At Week 24, dupilumab significantly improved Dermatology Life Quality Index (DLQI) total score versus placebo with a difference of -3.2 (95% CI -5.2 to -1.1) and improved Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) total score versus placebo with a difference of -8.6 (95% CI -14.6 to -2.6); EQ-VAS score difference versus placebo was 6.0 (95% CI 0.9 to 11.2) at Week 24 ^[2].
The prescribing information now includes recommended CSU dosing and pediatric weight-based regimens for ages 2 years to 17 years; for pediatric patients 2 years to 5 years: 5 to less than 15 kg — 200 mg every 4 weeks (Q4W); 15 to less than 30 kg — 300 mg every 4 weeks (Q4W) ^[1].

Safety & Tolerability

Hypersensitivity reactions including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness, angioedema, urticaria, rash, erythema nodosum, and erythema multiforme have occurred; the label directs discontinuation in the event of a hypersensitivity reaction ^[1].
Conjunctivitis, keratitis, and blepharitis are listed as warnings/precautions and the label advises patients to promptly report new or worsening eye symptoms ^[1].
Eosinophilic conditions and related complications are noted in warnings and precautions, with advice to be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, particularly when reducing oral corticosteroids ^[1].
In clinical trials for chronic spontaneous urticaria, the adverse reaction reported at an incidence ≥2% was injection site reactions ^[1].

Study Design

The updated indication in the prescribing information covers chronic spontaneous urticaria in adult and pediatric patients aged 2 years and older who remain symptomatic despite H1 antihistamine treatment; the DailyMed labeling was revised in April 2026 to reflect changes to Indications and Dosage for CSU and pediatric dosing tables ^[1]. The LIBERTY-CSU CUPID Study A was a double-blind, phase 3 randomized trial in patients aged ≥6 years that randomized patients to dupilumab 300 mg q2w (n = 70) or placebo q2w (n = 68) and evaluated HRQoL endpoints at Week 12 and Week 24; the trial reported DLQI, CU-Q2oL and EQ-VAS differences at Week 24 ^[2]. Clinicians should consult current prescribing information for full dosing guidance. The FDA label metadata lists a label effective date of April 22, 2026 and notes a most recent supplemental approval date of 2026-07-15 in the FDA prescribing information summary ^[1]^[3].

FAQ

Q1 What is dupilumab (Dupixent) approved for in CSU?

Dupixent is indicated for the treatment of adult and pediatric patients aged 2 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. The label notes limitations of use that it is not indicated for other forms of urticaria and that it is intended for use under the guidance of a healthcare provider. The prescribing information revision reflecting CSU dosing and indication was published April 2026.

Q2 How does dupilumab work?

Dupilumab is a human monoclonal IgG4 antibody that binds to the interleukin-4 receptor alpha (IL-4Rα) subunit, inhibiting IL-4 signaling through the Type I receptor and inhibiting both IL-4 and IL-13 signaling through the Type II receptor. Blocking IL-4Rα inhibits IL-4- and IL-13-mediated inflammatory responses, including cytokine and chemokine release and IgE-related pathways, although the mechanism has not been definitively established.

Q3 What is the recommended dose of dupilumab for pediatric CSU?

For pediatric patients 2 years to 5 years of age with chronic spontaneous urticaria, the label recommends no initial loading dose and weight-based dosing: 5 to less than 15 kg — 200 mg (one 200 mg injection) every 4 weeks (Q4W); 15 to less than 30 kg — 300 mg (one 300 mg injection) every 4 weeks (Q4W). For pediatric patients 6 years to 17 years of age the label provides initial loading doses and subsequent dosing by weight categories; clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects and safety considerations?

The prescribing information lists injection site reactions as an adverse reaction reported at an incidence ≥2% in chronic spontaneous urticaria trials. Warnings and precautions in the label include hypersensitivity reactions (including anaphylaxis and other severe immune-mediated reactions), conjunctivitis, keratitis and blepharitis, eosinophilic conditions, and guidance on not abruptly discontinuing corticosteroids. The label advises prompt reporting of new or worsening eye symptoms and treating pre-existing helminth infections prior to initiation.

Clinicians should consult current prescribing information for complete dosing guidance.

Dupilumab (Dupixent) Label Updated for Pediatric CSU, Weight-Based Dosing from 2 Years

Direct Clinical Takeaway & Evidence Summary

Dupilumab (Dupixent) Label Updated for Pediatric CSU, Weight-Based Dosing from 2 Years

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Cite & Reference This Monograph

Get weekly clinical updates for Dermatology in your inbox.

Related Clinical Updates

Adapalene–Benzoyl Peroxide Gel (Differin Epiduo) Added to FDA Rx‑to‑NonRx Switch List 5/22/2026

risankizumab pediatric approval: weight‑based 55 mg for <40 kg in ages 6+

FDA Adds Bemotrizinol to OTC Sunscreen Monograph

Verified HCP Portal